

Medivo Study Finds HCV Positivity Rates Are 250% Higher Among Baby Boomers


Analysis Of Over 4,000,000 Patients Was Selected As A Poster Of Distinction At Digestive Disease Week

New York, NY – May 22, 2015 - Medivo, Inc., a leader in lab data analytics, presented an abstract entitled “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV Following the 2012 CDC Call to Action: Results from a Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, 2015.



The study was conducted by Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, MD; Tatiana Sorokina, MSc; Ajitpal Singh Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, MD from the University of Chicago, Chicago, IL.

About the study: In August 2012, the Centers for Disease Control and Prevention (CDC) called for all Americans in the “Baby Boomer” generation (born 1945 - 1965) to have a one-time screening test for hepatitis C (HCV). The purpose of this study is to examine the positivity rates in 4,961,282 adults screened for HCV antibody (Ab) between August 2011 and July 2014, and the viral genotypes of the HCV+ subgroup. Logistic regression analysis showed that Baby Boomers were 250% more likely to have a + HCV antibody test than non-Baby Boomers. However, over time HCV positivity rates among Baby Boomers fell compared to non-Baby Boomers as more Baby Boomers were screened.



According to Dr. Bhan, Medivo’s Chief Medical Officer, “This research shows that analysis of lab test results offers critically important, immediately actionable information that helps in the surveillance of a communicable disease like HCV.”

The poster is available for viewing online in the Medivo Resource Library. Questions about this study should be directed to Carol Smyth at csmyth@medivo.com.

About Medivo

Medivo is a health data analytics company that unlocks the power of lab data to improve health. Medivo is the largest source of lab data in the U.S., with access to over 150M patients through its nationwide network of partner labs. Medivo analyzes large, de-identified data sets and shares its findings with the medical community at large, as well as with its life science, payer and lab partners, to ensure that appropriate available treatments are provided to patients sooner. Founded in 2010, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit <http://www.medivo.com>.

